Covered recipient · General Payments record
MATTHEW DAVID GALSKY
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$283,390.67
- Reported across 236 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,500.03 | 2 |
| Food and Beverage | $879.69 | 12 |
| Consulting Fee | $610.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $1,998.38 | 4 |
| Janssen Research & Development, LLC | $345.32 | 1 |
| PFIZER INC. | $245.35 | 3 |
| E.R. Squibb & Sons, L.L.C. | $195.00 | 3 |
| ABBVIE INC. | $115.60 | 1 |
| Gilead Sciences, Inc. | $51.79 | 1 |
| Tempus AI, Inc | $38.28 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $115.60 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103767818 | CMS |
| E.R. Squibb & Sons, L.L.C. | $135.00 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101439348 | CMS |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101439350 | CMS |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101439352 | CMS |
| Gilead Sciences, Inc. | $51.79 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133829155 | CMS |
| Janssen Research & Development, LLC | $345.32 | 09/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1077589931 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141623445 | CMS |
| Merck Sharp & Dohme LLC | $610.00 | 02/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141745699 | CMS |
| Merck Sharp & Dohme LLC | $1,154.71 | 04/23/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1141552410 | CMS |
| Merck Sharp & Dohme LLC | $83.67 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141552408 | CMS |
| PFIZER INC. | $135.00 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131413461 | CMS |
| PFIZER INC. | $39.11 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131470644 | CMS |
| PFIZER INC. | $71.24 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131470648 | CMS |
| Tempus AI, Inc | $16.83 | 02/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150164901 | CMS |
| Tempus AI, Inc | $21.45 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150164903 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.